Lecanemab: nueva opción terapéutica en la enfermedad de Alzheimer precoz

Abstract

Introduction: Neurodegenerative diseases continue to constitute a worldwide public health challenge. Alzheimer's disease is the most common form of these neurodegenerative disorders and the most prevalent cause of dementia. The pharmaceutical field has proposed using Lecanemab, a monoclonal antibody targeting beta-amyloid protein, to slow the progression of the disease as long as it is in its early stages. Objective: To describe using Lecanemab in early Alzheimer's disease. Methodology: A narrative literature review was conducted on Lecanemab in early Alzheimer's disease, including articles from indexed databases in Spanish and English from 2019 to 2023. The articles comprised systematic reviews, bibliographic reviews, meta-analyses, and observational studies, with concise and clear methodology and results. Keywords were validated with MeSH/DeCS medical descriptors and combined with Boolean operators "AND," "OR," and "NOT." Results: The use of Lecanemab in mild Alzheimer's disease has shown a reduction in beta-amyloid plaques, a protein involved in the pathogenesis of the condition. Conclusion: Lecanemab is supported by the scientific community due to its high efficacy in reducing beta-amyloid deposits in the early stages of the disease its use.